drug · oligonucleotide

elebsiran

Phase 3updated 5mo ago

by $VIR Vir Biotechnology, Inc.🔗 ChEMBL

Phase 3

community read0 votes

Oligonucleotide drug with a maximum clinical stage of Phase 2 (across all indications), with 5 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying elebsiran

phase3A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infectionactive not recruitingn=124
phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtiderecruitingn=150
phase2A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infectionactive not recruitingn=100

News(1)

Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead S…
fiercebiotech · 6d ago

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 50m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · oligonucleotide

save

elebsiran

Phase 3updated 5mo ago

by $VIR Vir Biotechnology, Inc.🔗 ChEMBL

Phase 3

community read0 votes

Oligonucleotide drug with a maximum clinical stage of Phase 2 (across all indications), with 5 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying elebsiran

phase3A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infectionactive not recruitingn=124
phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtiderecruitingn=150
phase2A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infectionactive not recruitingn=100

News(1)

Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead S…
fiercebiotech · 6d ago

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 50m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

elebsiran

all catalysts(0)

Trials studying elebsiran

News(1)

Report a data issue

comments(0)

elebsiran

all catalysts(0)

Trials studying elebsiran

News(1)

Report a data issue

comments(0)